Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 12 Saturday Friday Sunday Monday Tuesday Publication Only MONDAY, JUNE 3 RD 8:00am - 12:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster 7029 Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6. Andorsky D Andorsky D, Gandhi M, Ibrahimi S, Sharman J Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 9:00am - 12:00pm Hall A Poster 7078 Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM). Lasica M Matous J Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 9:00am - 12:00pm Hall A Poster 5589 Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study. Yonemori K Richardson D Gynecologic Cancer 9:00am - 12:00pm Hall A Poster 7522 Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9. Sborov D Ramakrishnan A Hematologic Malignancies—Plasma Cell Dyscrasia 9:00am - 12:00pm Hall A Poster 5582 Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single- agent mirvetuximab soravtansine. O'Malley D Coleman R, Moore K Gynecologic Cancer 9:00am - 12:00pm Hall A Poster 5595 Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/ BRCA2 mutation (BRCAm) status. Van Nieuwenhuysen E Pepin JT, McCollum M Gynecologic Cancer 9:00am - 12:00pm Hall A Poster 5606 Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial. Mirza M Buscema J, Eshed H, Coleman R Gynecologic Cancer 9:00am - 12:00pm Hall A Poster 5607 Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/ RUBY trial. Lokich E Monk B, Cloven N, Willmott L Gynecologic Cancer